Assenagon Asset Management S.A. Decreases Stake in Integra LifeSciences Holdings Corporation $IART

Assenagon Asset Management S.A. reduced its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 20.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 417,407 shares of the life sciences company’s stock after selling 108,895 shares during the period. Assenagon Asset Management S.A.’s holdings in Integra LifeSciences were worth $3,932,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in IART. Global Retirement Partners LLC acquired a new stake in Integra LifeSciences during the 4th quarter worth about $25,000. Osaic Holdings Inc. grew its stake in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Integra LifeSciences by 145.9% in the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth about $124,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on IART. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and upped their target price for the company from $11.00 to $16.00 in a research report on Thursday, May 28th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. Truist Financial cut their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Finally, Wells Fargo & Company increased their price target on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $16.20.

Integra LifeSciences Trading Down 0.1%

Shares of Integra LifeSciences stock opened at $18.74 on Tuesday. The firm has a 50-day simple moving average of $15.00 and a two-hundred day simple moving average of $12.55. The company has a market cap of $1.46 billion, a P/E ratio of -2.90, a price-to-earnings-growth ratio of 1.30 and a beta of 1.24. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $18.92. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same period last year, the firm earned $0.41 EPS. The company’s quarterly revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.